View in EDS

The association of brain-derived neurotrophic factor with the diagnosis and treatment response in depression

Saved in:
Bibliographic Details
Title: The association of brain-derived neurotrophic factor with the diagnosis and treatment response in depression
Authors: Matea Nikolac Perkovic, Martin Gredicak, Marina Sagud, Gordana Nedic Erjavec, Suzana Uzun, Nela Pivac
Source: Expert Review of Molecular Diagnostics. 23:283-296
Publisher Information: Informa UK Limited, 2023.
Publication Year: 2023
Subject Terms: Antidepressive Agents / therapeutic use, Depressive Disorder, Major / diagnosis, Depressive Disorder, Major, Genotype, Depression, Brain-Derived Neurotrophic Factor / genetics, Brain-Derived Neurotrophic Factor, Depression / etiology, Polymorphism, Single Nucleotide, Depression / drug therapy, Antidepressive Agents, 3. Good health, Depressive Disorder, Major / drug therapy, BDNF, BDNF Val66Met, antidepressants, depression, treatment response, Depressive Disorder, Major / genetics, Humans, Brain-Derived Neurotrophic Factor / therapeutic use, Depression / diagnosis
Description: Recent evidence from the studies evaluating the association between brain-derived neurotrophic factor (BDNF) concentration/levels, BDNF Val66Met (rs6265) polymorphism, and major depressive disorders, referred as depression, and the association between BDNF levels and/or BDNF Val66Met with the treatment response in depression is presented.This mini review focuses on the changes in the peripheral BDNF levels in blood (serum, plasma, platelets) in patients with depression before or after treatment with antidepressant drugs or different therapeutic strategies. In addition, this review describes the recent data on the possible association between different antidepressants/therapeutic strategies and the particular BDNF Val66Met genotypes, evaluating the risk alleles associated with the response in patients with depression.BDNF has an important role in the pathophysiology and treatment response in depression. Most data reveal that peripheral BDNF levels are lower before than after antidepressant treatment and might be used as potential biomarkers of therapeutic response. Novel therapeutic strategies should target restoring/increasing BDNF levels.
Document Type: Article
File Description: application/pdf
Language: English
ISSN: 1744-8352
1473-7159
DOI: 10.1080/14737159.2023.2200937
Access URL: https://pubmed.ncbi.nlm.nih.gov/37038358
https://urn.nsk.hr/urn:nbn:hr:105:267765
https://doi.org/10.1080/14737159.2023.2200937
Rights: CC BY NC
Accession Number: edsair.doi.dedup.....e1b87f2a733671b4931e9d897e7294c9
Database: OpenAIRE
Description
Abstract:Recent evidence from the studies evaluating the association between brain-derived neurotrophic factor (BDNF) concentration/levels, BDNF Val66Met (rs6265) polymorphism, and major depressive disorders, referred as depression, and the association between BDNF levels and/or BDNF Val66Met with the treatment response in depression is presented.This mini review focuses on the changes in the peripheral BDNF levels in blood (serum, plasma, platelets) in patients with depression before or after treatment with antidepressant drugs or different therapeutic strategies. In addition, this review describes the recent data on the possible association between different antidepressants/therapeutic strategies and the particular BDNF Val66Met genotypes, evaluating the risk alleles associated with the response in patients with depression.BDNF has an important role in the pathophysiology and treatment response in depression. Most data reveal that peripheral BDNF levels are lower before than after antidepressant treatment and might be used as potential biomarkers of therapeutic response. Novel therapeutic strategies should target restoring/increasing BDNF levels.
ISSN:17448352
14737159
DOI:10.1080/14737159.2023.2200937